The relation between Anti Mullerian hormone and hormone receptor status
of breast cancer: a cross-sectional study
Abstract
Background: Estrogen is the strongest risk factor for breast cancer,
especially hormone receptor positive subtypes. Anti- Müllerian hormone
(AMH) can stimulate apoptosis, reduces breast tumor growth, and also has
several actions in the steroid biosynthetic pathway. Therefore, there
may be a correlation between AMH and breast cancer. Aims: In this study,
we evaluate the correlation between AMH levels and the estrogen receptor
(ER) or progesterone receptor (PR) status of breast cancer. Methods:
This retrospective study was performed at two University Hospitals
between August 2018 and April 2019. Serum AMH level, ER and PR status of
the tumors were extracted from medical records. Results: Totally 100
premenopausal women with biopsy proven breast cancer were included in
our study. AMH level was slightly higher in patients with ER positive
than those with ER negative tumors, however, the difference was not
significant (3.33 ± 3.15 vs 2.71± 2.06, p-value =0.69). In categorized
AMH level, however, we could not find any significant differences
between ER positive and negative as well as PR positive and negative
patients. Conclusion: This study shows that there might be an
association between serum AMH and breast cancer subtype regarding
hormone receptors. We propose larger studies to be performed in order to
verify this important issue further.